A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

Locally Advanced Rectal Cancer (LARC) Clinical Trial

Official title: Phase II, Multicenter, Open-label, Non-randomized Study of Neoadjuvant Chemotherapy NALIRINOX (5-FU/LV + Oxaliplatin + Nal-IRI) Followed by Chemoradiotherapy in Patients With Rectal Cancer in a Watch-and-wait Program

Status Completed

Clinical Trial Summary

This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation after NAC (Neoadjuvant Chemotherapy) with NALIRINOX (5-FU [fluorouracil)/LV [Leucovorin calcium] + oxaliplatin + nal-IRI [Liposomal Irinotecan]) and chemoradiotherapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Locally Advanced Rectal Cancer (LARC)
• Rectal Neoplasms

• NCT number: NCT04009876
• Study type: Interventional
• Source: Fundación de investigación HM
• Status: Completed
• Phase: Phase 2
• Start date: May 1, 2019
• Completion date: October 21, 2022